Clovis Oncology Inc
NASDAQ:CLVS
Intrinsic Value
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional... [ Read More ]
There is not enough data to reliably calculate the intrinsic value of CLVS.
Clovis Oncology Inc's market capitalization is 21.9m USD.
CLVS stock price is 0.093 USD.
CLVS.
CLVS. Open DCF Valuation
CLVS. Open Relative Valuation
CLVS.
CLVS's Revenue has dropped by 15% over the past 12 months.
CLVS's ROE (Return on Equity) has significantly decreased in the last 3 years from 193% to 78%.
CLVS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -91% to -71%, and is approaching profitability.
CLVS has negative Operating Income for the last twelve months.
CLVS has negative Net Income for the last twelve months.
CLVS's ROE (Return on Equity) for the past 12 months is very high and is equal to 78%.
CLVS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -71%.
CLVS has positive Gross Profit for the last twelve months.
CLVS's long-term liabilties (765m USD) exceed its long-term assets (347m USD).
CLVS has negative Free Cash Flow for the last twelve months.
CLVS's short-term liabilties (748m USD) exceed its short-term assets (102m USD).
CLVS has very high three-year average ROE (Return on Equity): 981%. The company is very efficient at transforming stockholders' equity into net income.
CLVS has negative three-year average ROIC (Return on Invested Capital): -94%. The company is not efficient at using invested capital to generate operating income.
CLVS's D/E (Debt to Equity) is very low and is equal to 0.
CLVS's Altman Z-Score is very low and is equal to -16.17.
CLVS doesn't generate enough operating income (-207m USD) to safely cover interest payments on its debt (10m USD).
Fundamental Analysis
Clovis Oncology Inc
Balance Sheet Decomposition
Clovis Oncology Inc
| Current Assets | 102.2m |
| Cash & Short-Term Investments | 58.3m |
| Receivables | 22.6m |
| Other Current Assets | 21.3m |
| Non-Current Assets | 244.6m |
| PP&E | 21.5m |
| Intangibles | 119.4m |
| Other Non-Current Assets | 103.6m |
| Current Liabilities | 747.9m |
| Accounts Payable | 18.1m |
| Accrued Liabilities | 68.8m |
| Other Current Liabilities | 661m |
| Non-Current Liabilities | 16.8m |
| Other Non-Current Liabilities | 16.8m |
Earnings Waterfall
Clovis Oncology Inc
|
Revenue
|
133m
USD
|
|
Cost of Revenue
|
-37m
USD
|
|
Gross Profit
|
96.1m
USD
|
|
Operating Expenses
|
-302.7m
USD
|
|
Operating Income
|
-206.7m
USD
|
|
Other Expenses
|
-45.2m
USD
|
|
Net Income
|
-251.9m
USD
|
Free Cash Flow Analysis
Clovis Oncology Inc
CLVS Profitability Score
Profitability Due Diligence
Clovis Oncology Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Clovis Oncology Inc's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
CLVS Solvency Score
Solvency Due Diligence
Clovis Oncology Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Score
Clovis Oncology Inc's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CLVS Price Targets Summary
Clovis Oncology Inc
Ownership
CLVS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
CLVS Price
Clovis Oncology Inc
| Average Annual Return | -44.71% |
| Standard Deviation of Annual Returns | 9.28% |
| Max Drawdown | -100% |
| Market Capitalization | 21.9m USD |
| Shares Outstanding | 235 406 940 |
| Percentage of Shares Shorted | 20.03% |
CLVS News
Last Important Events
Clovis Oncology Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Clovis Oncology Inc
Company Profile
Clovis Oncology Inc
Country
Industry
Market Cap
Dividend Yield
Description
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. The company is headquartered in Boulder, Colorado and currently employs 413 full-time employees. The company went IPO on 2011-11-16. The firm is focused on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and additional international markets. Its segments include U.S. and ex-U.S. Its product, Rubraca, is an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) marketed in the United States for two indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and an indication specific to metastatic castration-resistant prostate cancer (mCRPC). Its FAP-2286, is an investigational diagnostic and therapeutic agent targeting fibroblast activation protein (FAP). The company also provides Lucitanib, which is an investigational, oral, potent angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3).
You don't have any saved screeners yet
